Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics

Pathogenesis, prevention, and treatment of diabetic nephropathy

1998 • 560 citations

Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury

2003 • 518 citations

MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy

2008 • 397 citations

Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy

2000 • 337 citations

Acute-Phase Markers of Inflammation and Glomerular Structure in Patients with Type 2 Diabetes

2005 • 286 citations

Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis.

1998 • 285 citations

Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy

2000 • 266 citations

Angiotensin II Participates in Mononuclear Cell Recruitment in Experimental Immune Complex Nephritis Through Nuclear Factor-κB Activation and Monocyte Chemoattractant Protein-1 Synthesis

1998 • 226 citations

Advanced glycation end products, oxidant stress and vascular lesions

1997 • 215 citations

Protection of the kidney by thiazolidinediones: An assessment from bench to bedside

2006 • 214 citations

Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis

2004 • 190 citations

ACE Inhibitors Improve Diabetic Nephropathy Through Suppression of Renal MCP-1

2003 • 179 citations

Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats

2006 • 168 citations

Aldosterone Blockade Attenuates Urinary Monocyte Chemoattractant Protein-1 and Oxidative Stress in Patients with Type 2 Diabetes Complicated by Diabetic Nephropathy

2006 • 108 citations

Mechanical Stretch Induces Monocyte Chemoattractant Activity via an NF-κB-Dependent Monocyte Chemoattractant Protein-1-Mediated Pathway in Human Mesangial Cells

2005 • 90 citations

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)

2009 • 87 citations

Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy

2009 • 71 citations

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

2004 • 63 citations

Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus

2009 • 62 citations

Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential

2008 • 57 citations

Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats

2005 • 52 citations

Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression

2008 • 29 citations

Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.

2006 • 29 citations

Is proteinuria a plausible target of therapy?

2004 • 24 citations

Rosiglitazone Ameliorates Diabetic Nephropathy by Inhibiting Reactive Oxygen Species and Its Downstream-Signaling Pathways

2007 • 21 citations

Monocyte chemoattractant protein-1 and diabetic nephropathy

2007 • 1 citations